表观扩散系数评价骨肉瘤化疗疗效的价值

摘要

Objective To investigate the application value of apparent diffusion coefficient (ADC) in monitoring the effect of neoadjuvant chemotherapy for osteosarcoma. Methods Twenty-eight osteosarcoma patients underwent MRI before and after the neoadjuvant chemotherapy. ADC values of the lesions were measured before and after treatment. The differences in ADC values before and after treatment in responders and non-responders were analyzed. Results After the neoadjuvant chemotherapy, 21 patients and 7 patients were categorized into the responder group and the non-responder group respectively. The mean pre-treatment ADC values of the responder group and the non-responder group were (1.12 ± 0.16)×10-3 mm2/s and (1.57 ± 0.20)×10-3 mm2/s, respectively. The mean post-treatment ADC values of the responder group and the non-responder group were (2.33 ± 0.18)×10-3 mm2/s and (1.97 ± 0.22)×10-3 mm2/s respectively. The differences in the ADC values between the two groups before and after chemotherapy were statistically different (P < 0.05). The difference in the rates of change of ADC values in the responder and non-responder groups before and after treatment was significant (P < 0.05). Conclusions ADC values enable a good short-term response evaluation for osteosarcoma and the pre-treatment ADC value indicates significant predictive value for responses to the treatment.%目的 探讨表观扩散系数(ADC)在骨肉瘤新辅助化疗疗效监测中的价值.方法 28例确诊骨肉瘤患者于化疗前后接受MRI扫描.按治疗疗效分为疗效良好组和疗效较差组,分析两组治疗前后ADC值差异.结果 28例骨肉瘤患者中疗效良好组21例,疗效较差组7例.治疗前疗效良好组和疗效较差组平均ADC值分别为(1.12±0.16)×10-3mm2/s和(1.57±0.20)×10-3mm2/s;治疗后分别为(2.33±0.18)×10-3mm2/s和(1.97±0.22)×10-3mm2/s,经独立样本t检验,差异均有统计学意义(P<0.05).两组治疗前后ADC值变化率比较,差异有统计学意义(P<0.05).结论 ADC值对于评价骨肉瘤新辅助化疗疗效方面有较好价值,且治疗前ADC值可用于预测疗效.